Stock listing

OTC:PGABF Prostatype Genomics AB Stock

US listing (OTC) of Prostatype Genomics AB · home listing Stockholm:PROGEN

Follow Prostatype Genomics AB into a list and get an email when it puts out news.

Home listing price · OMXSTO:PROGEN

0.089 SEK -0.000 (-0.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:PROGEN

Past year -84.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
0.085 – 0.092 SEKNov 20, 2026
Volume
1.08M sharesNov 20, 2026
Market cap
13.88M SEKAt the close on Nov 20, 2026 · price × 155.6M shares outstanding
52-week range
0.076 – 2.280 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
979,378 SEKMedian day 5.17M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Prostatype Genomics AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:PROGEN · Home0.089 SEK0.000 (-0.4%)1,083,9230.0920.0920.0850.090Close on Nov 20, 2026
Frankfurt:PGO0€0.0060 EUR+0.0002 (+3.4%)—€0.0042€0.0060€0.0042€0.0058Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:PROGEN · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
0.0890.000-0.4%0.0920.0920.0851,083,923
0.090-0.006-6.1%0.0950.0990.0882,061,478
0.0950.000-0.4%0.0960.0970.0931,213,406
0.096+0.001+0.8%0.0930.0960.0921,364,732
0.095+0.002+2.2%0.0930.0970.090962,304
0.093-0.004-4.5%0.0980.0980.0912,132,417
0.097-0.001-1.2%0.1010.1040.0971,571,880
0.099-0.003-2.9%0.1000.1050.0981,682,078
0.102-0.004-3.8%0.1060.1060.100643,770
0.106+0.002+1.4%0.1020.1060.0982,198,019
0.104-0.003-2.3%0.1060.1060.1001,385,130
0.107-0.001-0.9%0.1080.1090.1011,464,377
0.108+0.001+0.5%0.1070.1080.1001,388,204
0.1070.0000.0%0.1070.1120.1041,885,689
0.107+0.008+8.3%0.1040.1080.0972,597,708
0.099-0.002-2.2%0.1010.1040.0961,904,194
0.101-0.001-1.0%0.1010.1010.0914,928,286
0.102+0.006+6.2%0.0970.1050.0972,586,003
0.096-0.007-6.8%0.1030.1050.0962,104,575
0.103+0.001+1.0%0.0990.1050.0991,853,618
0.102+0.002+2.0%0.1000.1050.0953,882,475
0.100-0.004-3.8%0.1040.1050.0947,710,108
0.104-0.002-1.9%0.1100.1130.1023,010,539
0.106-0.009-7.4%0.1150.1180.1065,137,524
0.115+0.009+8.0%0.1050.1170.10011,548,477
0.106+0.001+0.5%0.1060.1090.0994,276,538
0.106+0.014+14.9%0.0920.1100.09213,201,840
0.092+0.005+6.3%0.0870.0930.0875,783,654
0.086-0.001-0.7%0.0870.0910.0835,658,802
0.087+0.001+1.2%0.0880.0880.07913,242,138
0.086-0.006-6.5%0.0910.0920.08611,239,079
0.092-0.002-2.5%0.0940.0940.0904,570,119
0.094+0.001+1.3%0.0910.0990.0889,136,840
0.093-0.004-3.9%0.0970.0990.09011,953,299
0.097+0.000+0.4%0.0970.1120.09520,499,473
0.097-0.008-7.6%0.1060.1070.09521,156,567
0.105-0.018-14.3%0.1220.1220.09418,399,426
0.122+0.006+5.6%0.1150.1240.1145,196,575
0.116-0.004-3.7%0.1220.1370.1138,449,379
0.120-0.023-16.1%0.1430.1480.11216,351,552
0.143-0.004-2.7%0.1470.1490.1365,903,132
0.147-0.009-5.8%0.1590.1610.1427,278,147
0.156-0.005-2.8%0.1610.1650.1532,117,241
0.161-0.005-2.7%0.1660.1700.1586,025,525
0.165+0.006+3.8%0.1590.1650.1572,619,833
0.159+0.003+1.9%0.1560.1610.1483,815,993
0.156-0.003-1.9%0.1600.1600.1532,995,014
0.159-0.011-6.5%0.1700.1700.1528,565,761
0.1700.0000.0%0.1730.1730.1597,368,268
0.170-0.005-2.9%0.1760.1810.15914,439,042
0.175+0.023+15.1%0.1520.1750.1528,600,388
0.152+0.005+3.4%0.1470.1530.1443,597,796
0.147+0.001+0.3%0.1470.1540.1434,023,053
0.147-0.001-0.3%0.1480.1570.1435,063,148
0.147+0.005+3.2%0.1430.1600.1436,713,060
0.143+0.003+2.5%0.1460.1600.13110,474,154
0.139-0.010-7.0%0.1500.1660.13714,639,284
0.150-0.009-5.4%0.1590.1630.1406,684,759
0.158-0.014-7.9%0.1730.1730.15215,178,822
0.172+0.016+9.9%0.1600.1800.15720,106,874
0.1560.0000.0%0.1610.1720.14031,159,252
0.156+0.030+23.3%0.1310.1600.13038,207,457
0.127+0.011+10.0%0.1180.1310.11719,077,580
0.115+0.008+7.0%0.1090.1200.1098,283,150

Splits

4 splits since 2022 · OMXSTO:PROGEN · every price before a split is adjusted for it

DayRatioWhat
92-for-35Split
179-for-97Split
1-for-1000Consolidation
67-for-64Split
Ticker
OTC:PGABF
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Prostatype Genomics AB news

Prostatype Genomics AB on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
15 in the last 12 months · 21 in all · newest Sep 17, 2026 · oldest 2025

Where Prostatype Genomics AB is listed

ListingExchangeCountryCurrency
Stockholm:PROGEN · Home listingStockholmSwedenSEK
OTC:PGABF · This pageOTCUnited StatesUSD
Frankfurt:PGO0FrankfurtGermanyEUR

Valuation

EV/sales 13.3× against a median of 1.6×: 7th lowest of 8 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
13.48M SEK
P/E
Loss
EV/sales
13.3×
EV/EBITDA
Negative EBITDA
Price/book
2.1×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Prostatype Genomics AB · OMXSTO:PROGENUS$1.36MUS$1.32Mn/a13.3×n/a2.1×n/a0.0×n/a
Telo Genomics Corp. · TSXV:TELOUS$2.80MUS$2.12Mn/an/an/an/an/an/a0.04
Advanced Biomed Inc. · NASDAQ:ADVBUS$2.73MUS$3.12M0.5×12.2×n/a0.2×n/a0.1×0.35
Innovotech Inc. · TSXV:IOTUS$2.66MUS$2.51Mn/a1.0×n/a1.5×−21.1%0.1×0.39
Qlife Holding AB · OMXSTO:QLIFEUS$2.49MUS$2.88Mn/a34.1×n/a9.6×n/a3.1×n/a
Physiomics PLC · LSE:PYCUS$2.46MUS$1.91Mn/a1.6×n/a3.6×−74.1%0.0×n/a
20/20 BioLabs, Inc. · NASDAQ:AIDXUS$2.10M−US$1.01Mn/a−0.5×n/a3.4×−317.8%0.9×1.41
Bluejay Diagnostics, Inc. · NASDAQ:BJDXUS$1.90M−US$5.43Mn/an/an/a0.3×n/a0.0×1.71
Accustem Sciences Inc · OTC:ACUTUS$1.90MUS$1.88Mn/an/an/an/an/an/a0.19
InVitro International · OTC:IVROUS$1.87MUS$644,26029.6×0.8×14.0×1.1×8.2%0.0×0.17
Co-Diagnostics, Inc. · NASDAQ:CODXUS$1.36MUS$2.21Mn/a2.6×n/a0.1×n/a0.2×2.16
Median of the othersUS$2.28MUS$2.02M15.1×1.6×14.0×1.3×−47.6%0.1×0.37

Team and board

Officers

OfficerRole
Fredrik RickmanCEO Prostatype Genomics AB

Board

DirectorRole
Anders LiljebladChariman of the Board
Anders LundbergBoard member
Håkan EnglundBoard Member
Jörgen DahlströmBoard member
Mattias PrageBoard Member
Michael HäggmanBoard Member

Events

QuarterResultsShare move
Q2 2023Aug 17, 2023 · Before open−10.2%
Q1 2023May 31, 2023 · Before open+7.2%
Q4 2022Feb 16, 2023 · Before open−1.6%
Q3 2022Nov 10, 2022 · Before open+0.5%
Q2 2022Aug 18, 2022 · Before open−2.5%
Q1 2022May 12, 2022 · Before open−3.1%
Q4 2021Feb 24, 2022 · Before open−22.1%
Quarter to Mar 31, 2021May 27, 2021−1.4%

Open Events

Financings

RaiseDateIn US dollars
New shares through exercise of warrants of series TO6
Closed: SEK 12.5M raised · SEK 0.1 a share · Vator Securities AB +2
Dealers: Vator Securities AB, Navia Corporate Finance AB, Birchtree Advisory AB
Buyers: Vator Securities AB (8,156,289 shares at SEK 0.10 in the Directed Share Issue (underwriting and compensation shares))
Insiders: Letters of intent from the Board of Directors, management and other warrant holders corresponding to approximately SEK 2.27 million
Use of proceeds: Liquidity and financial position of the company
Sep 17, 2026US$1.27M
Rights offering of units (shares and warrants of series TO6 and TO7)
Closed: SEK 47.4M raised · SEK 0.1 a unit · Warrants at SEK 0.1 · Navia Corporate Finance AB +2
Dealers: Navia Corporate Finance AB (co-lead), Birchtree Advisory AB (co-lead), Vator Securities AB
Insiders: Subscription commitments from existing major shareholders, including members of the Board of Directors, totalling approximately SEK 9.2 million
Use of proceeds: Accelerate commercialization of Prostatype, strengthen presence in prioritized markets and continue company development
Aug 3, 2026US$4.88M
Rights offering of units (shares and two series of warrants)
Update: about SEK 47.4M · SEK 0.8 a unit · Warrants at SEK 0.1 · Navia Corporate Finance AB +2
Dealers: Navia Corporate Finance AB (co-lead), Birchtree Advisory AB (co-lead), Vator Securities AB
Insiders: Subscription commitments from existing major shareholders, including members of the Board of Directors, of approximately SEK 9.2 million in aggregate
Use of proceeds: Continued Medicare reimbursement approval process and commercialization in the US and Europe, plus general corporate purposes
Jun 30, 2026US$4.88M
Warrant exercise of warrants of series TO5
Closed: SEK 11.5M raised · SEK 0.52 a share · Navia Corporate Finance AB +2
Dealers: Navia Corporate Finance AB, Gemstone Capital ApS, Nordic Issuing AB
Buyers: Tony Chouha (1 696 784 shares in the Directed Issue as underwriter); Ghanem Chouha (1 696 784 shares in the Directed Issue as underwriter)
Insiders: Pre-subscription commitments of approximately 22.2 percent (SEK 2.6 million) from board members and an existing warrant holder
Sep 18, 2025US$1.23M
Rights offering of units of new shares and warrants of series TO5
Closed: SEK 27.3M raised · One warrant of series TO5 gives the right to subscribe for one new share from 3… · Navia Corporate Finance AB +2
Dealers: Navia Corporate Finance AB (co-lead), Gemstone Capital ApS (co-lead), Nordic Issuing AB
Buyers: Gerald Andriole (set-off of accumulated net remuneration of approximately SEK 2.1 million)
Jun 19, 2025US$2.86M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in SEK

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue594.0K199.0K1.36M683.0K10.0K683.9K74.1K161.8K56.0K
Cost of revenue38.2M-1.72M-2.37M13.5M-2.50M14.9M6.69M-4.66M4.97M
Gross profit-37.6M1.92M3.73M683.0K2.51M-14.2M-6.61M4.82M-4.91M
Research and development1.46M2.21M3.23M3.51M1.49M2.41M1.25M2.52M2.06M
Selling, general and administrative13.5M8.49M5.11M6.49M
Operating income-39.1M-40.9M-39.2M-28.7M-15.5M-16.6M-7.86M-9.16M-4.63M
Depreciation and amortization2.19M1.98M1.88M1.90M88.5K149.1K104.8K154.1K194.6K106.5K
EBITDA-36.9M-38.9M-37.4M-26.8M-15.5M-16.5M-7.71M-8.97M-4.52M
Interest expense1.61M1.68M1.54M397.0K81.5K1.49M0684.2K156.9K0
Income before tax-44.5M-41.1M-41.4M-29.1M-15.6M-17.4M-8.55M-9.32M-4.75M
Income tax1.71M1.68M-148.1K-2-7.00K3.08K
Net income-44.5M-41.1M-41.4M-29.1M-15.6M-17.4M-8.55M-9.32M-4.75M
Earnings per share, basic-1.32-13.67-12.04-7.72-10.64-25.16-613.49-100.94-0.17

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents9.07M9.42M2.68M4.81M9.83M15.9M2.69M8.21M10.5M
Short-term investments21.5M6.68M10.5M
Receivables1.50M1.78M1.53M2.50M1.07M1.20M331.8K1.12M892.8K246.5K
Inventory78.0K95.0K203.0K44.0K107.5K394.9K387.8K664.0K376.0K347.4K
Current assets10.6M11.8M25.9M14.2M21.6M17.5M9.44M4.48M9.70M11.2M
Property, plant and equipment3.60K14.1K28.2K35.3K39.5K92.3K212.6K
Total assets50.9M42.0M49.2M30.9M40.2M33.7M17.6M19.7M19.7M
Accounts payable2.73M2.52M9.45M2.18M1.17M1.78M962.2K652.5K1.18M996.9K
Current liabilities24.3M8.50M24.5M4.33M3.43M4.31M14.5M2.58M3.94M2.76M
Long-term debt0067.0K466.7K866.7K6.45M9.55M
Total debt5.30M67.0K11.7M867.0K1.27M1.47M6.85M9.58M2.09M
Total liabilities24.3M8.50M24.5M4.80M4.30M5.37M9.03M13.5M4.79M
Shareholders' equity26.5M33.5M24.7M26.2M35.9M28.3M8.55M6.22M14.9M
Shares outstanding33.8M3.00M3.44M3.77M1.47M691.9K13.9K92.3K28.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-23.8M-44.7M-29.1M-27.7M-16.1M-14.7M-7.25M-9.63M-5.71M-9.63M
Capital spending-258.0K-7.86M-8.56M-2-2.50M-26.2K-26.2K-3.26M-4.66M-27.0K
Free cash flow-24.1M-52.6M-37.7M-27.7M-18.6M-14.7M-7.27M-12.9M-10.4M-9.66M
Cash from investing-13.4M-8.36M-8.57M-2.50M-3.26M-2.16M-3.26M-4.66M-3.26M
Cash from financing36.8M59.8M28.9M18.9M23.0M31.1M15.3M7.38M8.10M7.38M
Change in cash-352.0K6.74M-8.81M-8.84M4.47M13.2M5.91M-5.52M-2.27M-5.52M

Open Financials

Cap table

Built by 6ix from Prostatype Genomics AB’s releases · as of Sep 17, 2026

Common shares
155,568,392
Fully diluted
182,909,244

Fully diluted

LineSharesAs of
Common shares155,568,392Sep 17, 2026
Warrants27,340,852Jun 5, 2025

Warrants and options

Lot
Warrants · 0.10 SEK · expiry not stated
Warrants · expiry not stated

Share count over time

CountShares
Sep 17, 2026155,568,392

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Michael Häggman
Member of the Board of Directors
Sale24,248SEK 0.07SEK 1,697Aug 31, 2026
Liljeblad & Co Aktiebolag
Closely associated with Anders Liljeblad (Chief Executive Officer (CEO)/Managing Directory)
Buy5,750,000SEK 0.10SEK 575KAug 31, 2026
Michael Häggman
Member of the Board of Directors
Buy357,500Aug 5, 2026
Håkan Englund
Member of the Board of Directors
Buy2,781,250Jul 29, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anders LiljebladChariman of the Board · Since at least Nov 5, 2026
Anders LundbergBoard member · Since at least Nov 5, 2026
Fredrik RickmanCEO Prostatype Genomics AB · Since at least Sep 17, 2026
Håkan EnglundBoard Member · Since at least Nov 5, 2026
Jörgen DahlströmBoard member · Since at least Nov 5, 2026
Mattias PrageBoard Member · Since at least Nov 5, 2026
Michael HäggmanBoard Member · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Prostatype Genomics AB.